Assessing operational readiness: Regulatory landscape and compliance in zimbabwe for medical devices and in vitro diagnostic medical devices

被引:0
|
作者
Chiku, Charles [1 ]
Maruta, Talkmore [2 ]
Mbiba, Fredrick [3 ]
Manasa, Justen [4 ]
机构
[1] WHO, Regulat & Prequalificat Dept, Geneva, Switzerland
[2] African Soc Lab Med, Lusaka, Zambia
[3] Biomed Res & Training Inst, Hlth Res Unit, Harare, Zimbabwe
[4] Univ Zimbabwe, Fac Med & Hlth Sci, Dept Oncol, Harare, Zimbabwe
来源
PLOS ONE | 2024年 / 19卷 / 05期
关键词
D O I
10.1371/journal.pone.0287495
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The regulation of medical devices and In Vitro Diagnostic (IVD) medical devices have lagged significantly, especially in low- and middle-income countries. Disparities in regulating medical and IVD medical devices in Africa are below the global average. This may translate to poor access to quality-assured medical and IVD devices, resulting in undesirable health outcomes. Operational readiness to regulate medical and IVD devices at the Medicines Control Authority of Zimbabwe (MCAZ) was assessed. The aim was to determine the strengths and gaps and propose an action plan that can be monitored and evaluated to assess progress over time. We used the World Health Organization (WHO) Global Benchmarking Tool for medical devices and IVDs methodology to evaluate regulatory oversight of these products. Purposive sampling was used for data collection using researcher-administered global benchmarking tool factsheets and document reviews to evaluate the implementation of the regulatory functions. The regulatory functions assessed were the National Regulatory System, Registration and Market Authorization, Vigilance, Market Surveillance and Control, Licensing Establishment, Regulatory Inspection, Laboratory Testing, and Clinical Trials Oversight. The MCAZ attained maturity level 1, with a regulatory system score of 79%, registration and market authorization 44%, vigilance 27%, market surveillance and control 40%, licensing establishment 62%, regulatory inspection 68%, laboratory testing 88%, and clinical trials 18%. Condoms and gloves were the only regulated medical devices in Zimbabwe. IVDs were not regulated by the MCAZ. This review showed that the regulatory system is not robust, fit for purpose, responsive, transparent, or proportionate to the risk classification of medical devices and IVDs. It is crucial to amend the Medicines and Allied Substance Control Act to incorporate the definition and classification of medical devices and IVDs, regulatory authority establishment, licensing and registration, quality management system, conformity assessment, post-market surveillance, labeling and instructions for use, capacity building and training, and international harmonization.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Navigating regulatory landscape: A qualitative exploration of medical devices and in vitro diagnostic medical devices oversight in Zimbabwe through key stakeholder perspectives
    Chiku, Charles
    Maruta, Talkmore
    Mbiba, Fredrick
    Manasa, Justen
    [J]. PLOS ONE, 2024, 19 (05):
  • [2] NEW PROPOSAL FOR EUROPEAN UNION REGULATIONS ON MEDICAL DEVICES AND IN VITRO DIAGNOSTIC MEDICAL DEVICES
    Yaneva-Deliverska, Mariela
    [J]. JOURNAL OF IMAB, 2012, 18 (03): : 360 - 362
  • [3] A comparison study of Taiwan regulation and GHTF regulatory model on in vitro diagnostic medical devices
    Tsai, Wen-Wei
    Tu, Pei-Weng
    Lin, Hsin-Hui
    Wang, Yin-Hsuan
    Wu, Shiow-Ing
    Fan, Yin-Ting
    [J]. EXPERT REVIEW OF MEDICAL DEVICES, 2017, 14 (04) : 285 - 296
  • [4] Performance evaluation of in vitro diagnostic medical devices: Methodology and differences compared to studies on other medical devices
    Grifa, Rosa Anna
    Pozzoli, Giacomo
    [J]. MICROCHEMICAL JOURNAL, 2018, 136 : 279 - 282
  • [5] Performance evaluation study of the PAXgene™ blood RNA system in compliance with regulatory guidelines for in vitro diagnostic (IVD) medical devices.
    Guenther, K
    Riemenschneider, V
    Rainen, L
    Zhang, J
    Lauber, J
    Oelmueller, U
    Wyrich, R
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2005, 7 (05): : 663 - 663
  • [6] Scope of new regulation on in vitro diagnostic medical devices
    Hernandez, G. H.
    [J]. ANNALS OF NUTRITION AND METABOLISM, 2022, 78 (SUPPL 3) : 7 - 7
  • [7] Safety of high risk in vitro diagnostic medical devices
    Halbauer, J.
    Siekmeier, R.
    Funk, M.
    [J]. BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2009, 52 (06) : 610 - 618
  • [8] Regulatory Reticence and Medical Devices
    Fox, Daniel M.
    Zuckerman, Diana M.
    [J]. MILBANK QUARTERLY, 2014, 92 (01): : 151 - 159
  • [9] Regulatory Deficits in Medical Devices
    Freckmann, G.
    Pleus, S.
    Heinemann, L.
    Koschinsky, T.
    [J]. DIABETOLOGE, 2016, 12 (08): : 558 - 565
  • [10] The regulatory framework of medical devices
    Vaugelade, C.
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2019, 203 (05): : 257 - 263